[AsCNP_DDR] Poster Session for Symposium-40
Noteworthy drug discovery/research and development - Aiming for innovation -

Sun. Oct 13, 2019 4:40 PM - 6:10 PM Poster Hall (Multi-purpose Hall)

Chair: ‌Tetsurou KIKUCHI (New Drug Research Division, Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd.)

*Posters of this session will be displayed for three days from October 11 (Fri) to October 13 (Sun).

+Add all to schedule

4:40 PM - 4:45 PM

[AsCNP-DDR-1] Schizophrenia paradox - A material or an event –

^○Masanari ITOKAWA^{1, 2} (1. Tokyo Metropolitan Institute of Medical Science, 2. Tokyo Metropolitan Matsuzawa Hospital)

4:45 PM - 4:50 PM

[AsCNP-DDR-2] Balanced Activation of Striatal Output Pathways by Faster Off-Rate Phosphodiesterase 10A Inhibitors Potentially Leads to not only Antipsychotic-Like Effects but also Activation of the Prefrontal Cortex and Cognitive Improvement in Rodents

^○Haruhide KIMURA (Neuroscience Drug Discovery Unit, Research, Takeda Parmaceutical Company Limited)

4:50 PM - 4:55 PM

[AsCNP-DDR-3] SEP-363856, a Candidate Antipsychotic Compound with a Novel Non-D2 Mechanism of Action

^○Kazuki YABUUCHI¹, Kenneth KOBLAN², Robert GOLDMAN², Justine KENT², Seth HOPKINS², Antony LOBEL² (1. Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan, 2. Sunovion Pharmaceutical Inc.)

4:55 PM - 5:00 PM

[AsCNP-DDR-4] Development of oxytocin as a novel therapeutic for autism spectrum core symptoms by utilizing multimodal outcome measures

^○Hidenori YAMASUE (Department of Psychiatry, Hamamatsu University School of Medicine)

5:00 PM - 5:05 PM

[AsCNP-DDR-5] Study of ifenprodil effects on patients with methamphetamine dependence: study protocol for an exploratory randomized double-blind placebo-controlled trial

^○Toshihiko MATSUMOTO¹, Hiroko KOTAJIMA-MURAKAMI^{1, 2}, Ayumi TAKANO³, Yasukazu OGAI⁴, Daisuke FUNADA^{1, 5}, Yuko TANIBUCHI^{1, 6}, Hisateru TACHIMORI⁷, Kazushi MARUO⁸, Kazutaka IKEDA^{1, 2} (1. Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, 2. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 3. Department of Mental Health and Psychiatric Nursing Tokyo Medical and Dental University, 4. Social Psychiatry and Mental Health, Faculty of Medicine, University of Tsukuba, 5. Department of Psychiatry, Center Hospital, National Center of Neurology and Psychiatry, 6. Department of Psychiatry, Chiba Hospital, 7. Department of Clinical Research Promotion, Transrational Medical Center, National Center of Neurology and Psychiatry, 8. Department of Biostatistics, Faculty of Medicine, University of Tsukuba)

5:05 PM - 5:10 PM

[AsCNP-DDR-6] BPN14770, an allosteric inhibitor of Phosphodiesterase 4D (PDE4D) developed for the treatment of Fragile X syndrome and other brain disorders such as Alzheimer’s disease

^○Hiroko ONO¹, Chong ZHANG², Ying XU³, James M O’DONNELL^{2, 3}, Hidekuni YAMAKAWA¹, Naotaka HORIGUCHI¹, Toshiyuki ASAKI¹, Mark E GURNEY⁴ (1. Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., 2. Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, 3. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 4. Tetra Discovery Partners Inc.)

5:10 PM - 5:15 PM

[AsCNP-DDR-7] Novel delta opioid receptor agonist NC-2800: a promising therapeutic agent for emotional modulation

^○Eriko NAKATA (Nippon Chemiphar Co., Ltd.)

5:15 PM - 5:20 PM

[AsCNP-DDR-8] The pharmacological and clinical profile of vortioxetine, an antidepressant with multimodal activity

^○Bjarke EBERT (H. Lundbeck A/S)

5:20 PM - 5:25 PM

[AsCNP-DDR-9] AV-101 (4-Cl-KYN): A New Generation Oral NMDA Receptor Glycine Site Antagonist for Treatment of Major Depressive Disorder

^○Shawn K SINGH (VistaGen Therapeutics, Inc.)

5:25 PM - 5:30 PM

[AsCNP-DDR-10] Esketamine Intranasal Spray, Its Development for TRD in Japan

^○Yushin TOMINAGA¹, Nagahide TAKAHASHI², Ayako SHIRAISHI¹, Yuka NAMIKAWA¹, Aya YAMADA¹, Yuya YAMADA¹, Toshifusa SHU¹, Hiroko SHIMIZU¹, Peter ZANNIKOS³, Jaskaran SINGH³, David HOUGH³ (1. Janssen Japan R&D, 2. Hamamatsu University School of Medicine, 3. Janssen Research and Development, LLC )

5:30 PM - 5:35 PM

[AsCNP-DDR-11] R-Ketamine (or Arketamine) as a rapid-acting antidepressant

^○Kenji HASHIMOTO (Chiba University Center for Forensic Mental Health, Chiba, Japan)

Session information

[AsCNP_DDR] Poster Session for Symposium-40Noteworthy drug discovery/research and development - Aiming for innovation -

[AsCNP_DDR] Poster Session for Symposium-40
Noteworthy drug discovery/research and development - Aiming for innovation -